Nowadays, there are several therapeutic options for stage III BRAF mutated or wild-type melanoma in the adjuvant setting, but none of these have shown a statistically significant OS benefit (although dabrafenib/trametinib showed an important trend in favour of combination therapy over placebo), and all of these therapies have a toxicity profile that requires careful consideration [ 4 – 6 ].
← all excerpts
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial.
1
—
—